F071 Rheum-Derm Conditions for the General Dermatologist
DESCRIPTION
This course is designed to help general dermatologists recognize skin manifestations of rheumatologic diseases in their everyday practices. Learners will be able to formulate a plan including further orders/investigations needed and first line treatments. In addition, we will discuss common dermatologic procedures that can be performed to improve the lives of patients with rheumatologic skin disease
LEARNING OBJECTIVES
Recognize the most common dermatological findings in rheumatologic diseases including differentiating between cutaneous lupus and dermatomyositis
Complete necessary further workup for skin findings in rheumatologic diseases
Demonstrate how common derm procedures can improve skin disease for rheumatologic diseases
SCHEDULE
9:00 AM
Discussion
DIRECTOR
Lauren V. Graham, MD, PhD, FAAD
SPEAKERS
Anne Louise Marano, MD, FAAD
Christopher T Richardson, PhD, MD, FAAD
Paras Pankaj Vakharia, MD, PharmD, FAAD
DISCLOSURES
Lauren V. Graham, MD, PhD, FAAD
arGEN-X – Investigator(Grants/Research Funding); AstraZeneca – Consultant (1099 relationship)(Fees); Biogen – Investigator(Grants/Research Funding); clarivate – Consultant (1099 relationship)(Fees); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding);
Anne Louise Marano, MD, FAAD
Biogen – Investigator(Grants/Research Funding); Bristol Myers Squibb – Investigator(Grants/Research Funding); Immunovant – Consultant (1099 relationship)(Fees); Priovant Therapeutics – Investigator(Grants/Research Funding);
Christopher T Richardson, PhD, MD, FAAD
AstraZeneca – Investigator(Grants/Research Funding); Biogen – Advisory Board(Fees); Immunovant – Consultant (1099 relationship)(Fees); Incyte Corporation – Investigator(Grants/Research Funding); Merck – Consultant (1099 relationship)(Fees); Priovant – Advisory Board(Honoraria); Ribon Therapeutics – Investigator(Grants/Research Funding);
Paras Pankaj Vakharia, MD, PharmD, FAAD
No financial relationships exist with ineligible companies.